Cargando…

Adverse events following introduction of the ChAdOx1 nCoV-19 vaccine in Somalia in 2021: findings from a fragile setting and implications for the future

BACKGROUND: Vaccination against coronavirus disease 2019 (COVID-19) began in Somalia on 16 March 2021 with the Covishield (ChAdOx1 nCoV-19) vaccine. However, by the end of 2021, only a small percentage of the population had been fully vaccinated. As side effects play an important role in determining...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamayoun, Mohammad, Abdulrazak, Ibrahim, Farid, Muhammad, Malik, Mamunur Rahman, Mohamud, Mohammed Farah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Coronavirus (COVID-19) Collection
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169432/ https://www.ncbi.nlm.nih.gov/pubmed/35720961 http://dx.doi.org/10.1016/j.ijregi.2022.06.001

Ejemplares similares

Rates, types, and associated factors of acute adverse effects after the first dose of ChAdOx1 nCoV-19 vaccine administration in Thailand
por: Watcharananan, Sirapat Arthur, et al.
Publicado: (2021)

Does ChAdOx1-S and BNT162b2 heterologous prime-boost vaccination trigger higher rates of vaccine-related adverse events?
por: Haji, Alhan, et al.
Publicado: (2023)

Post ChAdOx1 nCoV-19 vaccination frontal lobe syndrome
por: Tapdia, Madhusudan, et al.
Publicado: (2022)

Clinical outcomes in individuals hospitalized with SARS-CoV-2 Delta variant (B.1.617.2) who had been vaccinated with Covishield (ChAdOx1) and Covaxin (BBV-152)
por: Munigela, Apoorva, et al.
Publicado: (2022)

The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study
por: Porntharukchareon, Thachanun, et al.
Publicado: (2023)

Autoimmune encephalitis following ChAdOx1-S SARS-CoV-2 vaccination
por: Kwon, Hyeryung, et al.
Publicado: (2021)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2023)

Massive cerebral venous sinus thrombosis in vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 serum: case report of a successful multidisciplinary approach
por: Mirandola, Laura, et al.
Publicado: (2022)

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial
por: Thuluva, Subhash, et al.
Publicado: (2023)

MOG antibody–associated encephalomyelitis mimicking bacterial meningomyelitis following ChAdOx1 nCoV-19 vaccination: a case report
por: Escolà, Jordi Kühne, et al.
Publicado: (2022)

Comment on ‘MOG antibody-associated encephalomyelitis mimicking bacterial meningomyelitis following ChAdOx1 nCoV-19 vaccination: a case report’
por: Finsterer, Josef, et al.
Publicado: (2022)

Lymphadenopathy subsequent to Covishield (ChAdOx1 nCoV-19) Corona virus vaccine: ultrasound findings and clinical implications
por: Sahoo, Soumya Swaroop, et al.
Publicado: (2022)

Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021)

A preliminary study on the effectiveness of maternal to neonatal transfer of antibodies against SARS-CoV-2 in the women vaccinated with heterologous CoronaVac–ChAdOx1
por: Pongsatha, Saipin, et al.
Publicado: (2023)

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
por: Fortunato, Francesca, et al.
Publicado: (2023)

WCN23-1093 First report of durability of antibody response in maintenance haemodialysis patients and kidney transplant recipients vaccinated with ChAdOx1 nCoV-19 vaccine: A prospective, multicentre, observational, study
por: CHAUHAN, S.
Publicado: (2023)

Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Depression following ChAdOx1-S/nCoV-19 vaccine
por: Uvais, N.A.
Publicado: (2022)

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
por: Greinacher, Andreas, et al.
Publicado: (2021)

Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales
por: Kerr, Steven, et al.
Publicado: (2022)

SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021
por: Laxmaiah, Avula, et al.
Publicado: (2021)

COVID-19 vaccine hesitancy in Ethiopia in 2021: a multicenter cross-sectional study
por: Erega, Besfat Berihun, et al.
Publicado: (2022)

COVID-19 hospital admissions and mortality among healthcare workers in South Africa, 2020–2021
por: Tlotleng, Nonhlanhla, et al.
Publicado: (2022)

Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination
por: Hyun, Hakjun, et al.
Publicado: (2021)

Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccination
por: Öcal, Osman, et al.
Publicado: (2021)

Reversible radiculomyelitis after ChAdOx1 nCoV-19 vaccination
por: Spataro, Rossella, et al.
Publicado: (2022)

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
por: Schultz, Nina H., et al.
Publicado: (2021)

Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination
por: Berlot, Giorgio, et al.
Publicado: (2022)

Venous sinus thrombosis following vaccination with ChAdOx1 nCov-19()
por: Morales Varas, G., et al.
Publicado: (2022)

LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
por: Garibashvili, Tamara, et al.
Publicado: (2022)

Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine
por: Krutzke, Lea, et al.
Publicado: (2022)

Primary series COVID-19 vaccine effectiveness among healthcare workers in Albania, February–December 2021
por: Rubin-Smith, Julia E., et al.
Publicado: (2023)

A review of epidemiology and public health control measures of COVID-19 variants in Hong Kong, December 2020 to June 2021
por: LAM, Ho Yeung, et al.
Publicado: (2021)

Trend of expansion of SARS-CoV-2 infection and COVID-19 burden in Gabon (Central Africa) in mid-2021, based on a serological survey
por: Iroungou, Berthe A., et al.
Publicado: (2022)

Evaluating the strategies to control SARS-CoV-2 Delta variant spread in New Caledonia, a zero-COVID country until September 2021
por: Ochida, Noé, et al.
Publicado: (2023)

SARS-CoV-2 B.1.214.1, B.1.214.2 and B.1.620 are predominant lineages between December 2020 and July 2021 in the Republic of Congo
por: Mfoutou Mapanguy, Claujens Chastel, et al.
Publicado: (2022)

BNT162b2 and ChAdOx1 nCoV-19 vaccinations, incidence of SARS-CoV-2 infections and COVID-19 hospitalisations in Scotland in the Delta era
por: Shah, Syed Ahmar, et al.
Publicado: (2022)

Second round statewide sentinel-based population survey for estimation of the burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population of Karnataka, India, during January-February 2021
por: Padma, M Rajagopal, et al.
Publicado: (2021)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
por: Berg, Adam, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a9ar0evrsvc05ai1qlevi68fmj